En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
INNOSUISSE
Numéro de projet
9959.1;5 PFLS-LS
Titre du projet
Novel feeder cell-free and animal product-free culture conditions for therapeutic use of human embryonic stem cells.
Titre du projet anglais
Novel feeder cell-free and animal product-free culture conditions for therapeutic use of human embryonic stem cells.

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Description succincte
Anzeigen
-
-
Anzeigen
Résumé des résultats (Abstract)
Anzeigen
-
-
Anzeigen

Textes saisis


CatégorieTexte
Description succincte
(Allemand)
Novel feeder cell-free and animal product-free culture conditions for therapeutic use of human embryonic stem cells.
Description succincte
(Anglais)
Novel feeder cell-free and animal product-free culture conditions for therapeutic use of human embryonic stem cells.
Résumé des résultats (Abstract)
(Allemand)
Human embryonic stem cells (hESC) hold the potential to cure many critical human diseases. However to date, the successful methods to expand these cells whilst retaining their pluripotency depends on animal-derived additives such as serum or their animal-derived substitutes, and the use of fibroblast feeder cells. Proposing a conceptually novel signalling-based approach, this project aims to develop an entirely novel, fully defined culture method which does not depend on serum or feeders, supports long-term growth and pluripotency of hESC cells and thus is ideally suited to GMP manufacture of cells for therapeutic applications.
Résumé des résultats (Abstract)
(Anglais)
Human embryonic stem cells (hESC) hold the potential to cure many critical human diseases. However to date, the successful methods to expand these cells whilst retaining their pluripotency depends on animal-derived additives such as serum or their animal-derived substitutes, and the use of fibroblast feeder cells. Proposing a conceptually novel signalling-based approach, this project aims to develop an entirely novel, fully defined culture method which does not depend on serum or feeders, supports long-term growth and pluripotency of hESC cells and thus is ideally suited to GMP manufacture of cells for therapeutic applications.